Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
NXL
NXL
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
NXL News
Nexalin Showcases Clinical Results at Neuromodulation Conference
5d ago
Newsfilter
Nexalin's Clinical Trial Shows Significant Improvements in Anxiety and Depression
Jun 10 2026
Newsfilter
Nexalin Secures U.S. Patent to Strengthen Market Position
Jun 04 2026
Newsfilter
Australian Stock Market Shows Signs of Recovery
May 31 2026
Yahoo Finance
Biotech Sector Regulatory Approvals and Collaborations
May 22 2026
NASDAQ.COM
U.S. Congress Supports Nexalin's Neurostimulation Research for Veterans
May 21 2026
Newsfilter
Nexalin Acquires PONM to Enhance HALO Clarity
May 19 2026
NASDAQ.COM
Nexalin Acquires PONM to Enhance Digital Health Platform
May 19 2026
Newsfilter
Nexalin's Technology Significantly Improves Sleep Quality
Apr 28 2026
Newsfilter
Nexalin Partners with Lindus Health to Advance Clinical Trial for HALO Clarity Device
Apr 23 2026
NASDAQ.COM
Nexalin Advances HALO™ Clarity Clinical Trial for Insomnia Treatment
Apr 22 2026
Newsfilter
Nexalin Advances Alzheimer's Treatment Technology in U.S. Regulatory Pathway
Apr 15 2026
NASDAQ.COM
Nexalin Advances Global Clinical Strategy for Alzheimer's Treatment
Apr 15 2026
Newsfilter
Nexalin Advances HALO Clarity Clinical Trial for Insomnia Treatment
Feb 24 2026
NASDAQ.COM
Nexalin Advances Drug-Free Insomnia Treatment Clinical Trial
Feb 24 2026
Newsfilter
Nexalin Advances Pivotal Insomnia Clinical Trial
Feb 24 2026
Benzinga
Show More News
